Most CEOs think they’re leading an AI transformation, but they’re managing a portfolio of pilots, and the two are not the same. The companies pulling ahead aren’t moving faster on the same path; they’re building proprietary intelligence through unique data, encoded workflows, and learning architectures that compound in ways no competitor can counter by writing a bigger check.
AI is set to boost managerial efficiency by streamlining tasks and providing quick answers. However, this rapid access to information presents a significant challenge for cultivating strategic leaders. Leadership traditionally develops through years of deep learning, questioning assumptions, and making complex decisions based on accumulated experience and pattern recognition.
During a recent TIME100 Talks panel in Cannes, a group of CEOs and executives from different sectors came together to discuss how artificial intelligence is changing creativity at their respective companies.
The biotech has entered into a licensing and collaboration agreement with Swedish company AlzeCure Pharma for rights to the latter’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856. QuantumCell is paying only $12m upfront, but a tail-heavy weighting to the deal with milestone payments means the total transaction could exceed $2.2bn.
Under a new five-year agreement, Haleon plans wider adoption of AI-powered tools to help employees “automate routine tasks, collaborate more effectively and focus on higher-value work,” the London-based company said in a July 1 announcement days after Microsoft revealed the deal. The Advil maker already used Microsoft 365 Copilot before the latest relationship upgrade.
